Immunotherapy in the Context of Aortic Valve Diseases.
Aortic valve disease
Calcification
Cardiovascular disease
Immune response
T cells
Journal
Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
accepted:
08
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
Aortic valve disease (AVD) affects millions of people around the world, with no pharmacological intervention available. Widely considered a multi-faceted disease comprising both regurgitative pathogenesis, in which retrograde blood flows back through to the left ventricle, and aortic valve stenosis, which is characterized by the thickening, fibrosis, and subsequent mineralization of the aortic valve leaflets, limiting the anterograde flow through the valve, surgical intervention is still the main treatment, which incurs considerable risk to the patient. Though originally thought of as a passive degeneration of the valve or a congenital malformation that has occurred before birth, the paradigm of AVD is shifting, and research into the inflammatory drivers of valve disease as a potential mechanism to modulate the pathobiology of this life-limiting pathology is taking center stage. Following limited success in mainstay therapeutics such as statins and mineralisation inhibitors, immunomodulatory strategies are being developed. Immune cell therapy has begun to be adopted in the cancer field, in which T cells (chimeric antigen receptor (CAR) T cells) are isolated from the patient, programmed to attack the cancer, and then re-administered to the patient. Within cardiac research, a novel T cell-based therapeutic approach has been developed to target lipid nanoparticles responsible for increasing cardiac fibrosis in a failing heart. With clonally expanded T-cell populations recently identified within the diseased valve, their unique epitope presentation may serve to identify novel targets for the treatment of valve disease. Taken together, targeted T-cell therapy may hold promise as a therapeutic platform to target a multitude of diseases with an autoimmune aspect, and this review aims to frame this in the context of cardiovascular disease, delineating what is currently known in the field, both clinically and translationally.
Identifiants
pubmed: 39017904
doi: 10.1007/s10557-024-07608-7
pii: 10.1007/s10557-024-07608-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : British Heart Foundation
ID : CH/17/1/32804
Pays : United Kingdom
Informations de copyright
© 2024. The Author(s).
Références
Otto CM, Prendergast B. Aortic-valve stenosis–from patients at risk to severe valve obstruction. N Engl J Med. 2014;371:744–56. https://doi.org/10.1056/NEJMra1313875 .
doi: 10.1056/NEJMra1313875
pubmed: 25140960
Lindman BR, Sukul D, Dweck MR, Madhavan MV, Arsenault BJ, Coylewright M, Merryman WD, Newby DE, Lewis J, Harrell FE Jr, et al. Evaluating medical therapy for calcific aortic stenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78:2354–76. https://doi.org/10.1016/j.jacc.2021.09.1367 .
doi: 10.1016/j.jacc.2021.09.1367
pubmed: 34857095
pmcid: 8647810
Dweck MR, Loganath K, Bing R, Treibel TA, McCann GP, Newby DE, Leipsic J, Fraccaro C, Paolisso P, Cosyns B, et al. Multi-modality imaging in aortic stenosis an EACVI clinical consensus document. Eur Heart J Cardiovasc Imaging. 2023. https://doi.org/10.1093/ehjci/jead153 .
doi: 10.1093/ehjci/jead153
pubmed: 37861420
pmcid: 10610741
Boudoulas H, Vavuranakis M, Wooley CF. Valvular heart disease: the influence of changing etiology on nosology. J Heart Valve Dis. 1994;3:516–26.
pubmed: 8000586
Wilson PWF, Kauppila LI, O’Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation. 2001;103:1529–34. https://doi.org/10.1161/01.CIR.103.11.1529 .
doi: 10.1161/01.CIR.103.11.1529
pubmed: 11257080
Freeman RV, Otto CM. Spectrum of calcific aortic valve disease. Circulation. 2005;111:3316–26. https://doi.org/10.1161/CIRCULATIONAHA.104.486738 .
doi: 10.1161/CIRCULATIONAHA.104.486738
pubmed: 15967862
Singh R, Strom JA, Ondrovic L, Joseph B, VanAuker MD. Age-related changes in the aortic valve affect leaflet stress distributions: implications for aortic valve degeneration. J Heart Valve Dis. 2008;17:290–8 (discussion 299).
pubmed: 18592926
Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, Alahdab F, Alashi A, Alipour V, Arabloo J, et al. Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990–2017. Circulation. 2020;141:1670–80. https://doi.org/10.1161/circulationaha.119.043391 .
doi: 10.1161/circulationaha.119.043391
pubmed: 32223336
Lindman BR, Clavel MA, Mathieu P, Iung B, Lancellotti P, Otto CM, Pibarot P. Calcific aortic stenosis. Nat Rev Dis Primers. 2016;2:16006. https://doi.org/10.1038/nrdp.2016.6 .
doi: 10.1038/nrdp.2016.6
pubmed: 27188578
pmcid: 5127286
Otto CM. Heartbeat: time to treat the whole patient, not just the valve, when calcific aortic stenosis is present. Heart. 2020;106:1621–3. https://doi.org/10.1136/heartjnl-2020-318316 .
doi: 10.1136/heartjnl-2020-318316
pubmed: 33046623
Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316–26. https://doi.org/10.1161/circulationaha.104.486738 .
doi: 10.1161/circulationaha.104.486738
pubmed: 15967862
Bartoli-Leonard F, Zimmer J, Aikawa E. Innate and adaptive immunity: the understudied driving force of heart valve disease. Cardiovasc Res. 2021;117:2506–24. https://doi.org/10.1093/cvr/cvab273 .
doi: 10.1093/cvr/cvab273
pubmed: 34432007
pmcid: 8783388
Erkhem-Ochir B, Tatsuishi W, Yokobori T, Ohno T, Hatori K, Handa T, Oyama T, Shirabe K, Saeki H, Abe T. Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosis. JTCVS Open. 2021;5:1–12. https://doi.org/10.1016/j.xjon.2020.11.007 .
doi: 10.1016/j.xjon.2020.11.007
pubmed: 36003161
Yu Chen H, Dina C, Small AM, Shaffer CM, Levinson RT, Helgadóttir A, Capoulade R, Munter HM, Martinsson A, Cairns BJ, et al. Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study. Eur Heart J. 2023;44:1927–39. https://doi.org/10.1093/eurheartj/ehad142 .
doi: 10.1093/eurheartj/ehad142
pubmed: 37038246
pmcid: 10232274
Yutzey KE, Demer LL, Body SC, Huggins GS, Towler DA, Giachelli CM, Hofmann-Bowman MA, Mortlock DP, Rogers MB, Sadeghi MM, et al. Calcific aortic valve disease: a consensus summary from the alliance of investigators on calcific aortic valve disease. Arterioscler Thromb Vasc Biol. 2014;34:2387–93. https://doi.org/10.1161/atvbaha.114.302523 .
doi: 10.1161/atvbaha.114.302523
pubmed: 25189570
pmcid: 4199903
Maganti K, Rigolin VH, Sarano ME, Bonow RO. Valvular heart disease: diagnosis and management. Mayo Clin Proc. 2010;85:483–500. https://doi.org/10.4065/mcp.2009.0706 .
doi: 10.4065/mcp.2009.0706
pubmed: 20435842
pmcid: 2861980
Park S, Chung WB, Lee KY, Jung MH, Jung HO, Chang K, Youn HJ. Trans-aortic flow turbulence and aortic valve inflammation: a pilot study using blood speckle imaging and (18)F-sodium fluoride positron emission tomography/computed tomography in patients with moderate aortic stenosis. J Cardiovasc Imaging. 2023;31:145–9. https://doi.org/10.4250/jcvi.2022.0118 .
doi: 10.4250/jcvi.2022.0118
pubmed: 37488920
pmcid: 10374388
Shimoni O, Rapp O, Klempner R, Segev A, Pounds C, Massalha E. Age disparity among severe aortic stenosis patients: AVR treatment rates and clinical outcomes among octogenarians. Eur Heart J. 2023;44:ehad655-2664. https://doi.org/10.1093/eurheartj/ehad655.2664 .
doi: 10.1093/eurheartj/ehad655.2664
Boskovski MT, Gleason TG. Current therapeutic options in aortic stenosis. Circ Res. 2021;128:1398–417. https://doi.org/10.1161/CIRCRESAHA.121.318040 .
doi: 10.1161/CIRCRESAHA.121.318040
pubmed: 33914604
Park SJ, Ok YJ, Kim HJ, Kim Y-J, Kim S, Ahn J-M, Kim D-H, Choi J-S, Kim JB. Evaluating reference ages for selecting prosthesis types for heart valve replacement in Korea. JAMA Netw Open. 2023;6:e2314671–e2314671. https://doi.org/10.1001/jamanetworkopen.2023.14671 .
doi: 10.1001/jamanetworkopen.2023.14671
pubmed: 37213100
pmcid: 10203891
Lieberman EB, Bashore TM, Hermiller JB, Wilson JS, Pieper KS, Keeler GP, Pierce CH, Kisslo KB, Harrison JK, Davidson CJ. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol. 1995;26:1522–8. https://doi.org/10.1016/0735-1097(95)00363-0 .
doi: 10.1016/0735-1097(95)00363-0
pubmed: 7594080
Jammoul N, Dupasquier V, Akodad M, Meunier PA, Moulis L, Soltani S, Macia JC, Robert P, Schmutz L, Steinecker M, et al. Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial. Am Heart J. 2024;270:13–22. https://doi.org/10.1016/j.ahj.2024.01.005 .
doi: 10.1016/j.ahj.2024.01.005
pubmed: 38253304
Iwasaki M, Konishi A, Takahara M, Kohsaka S, Okuda M, Hayashi T, Takamisawa I, Ishii H, Amano T, Shinke T, et al. Volume-outcome relationship in balloon aortic valvuloplasty: results of a consecutive, patient-level data analysis from a Japanese nationwide multicentre registry (J-SHD). BMJ Open. 2023;13:e073597. https://doi.org/10.1136/bmjopen-2023-073597 .
doi: 10.1136/bmjopen-2023-073597
pubmed: 37848296
pmcid: 10582855
Saleemi SA, Noaman S, Brookes J, Dick RJL. Clinical outcomes associated with balloon aortic valvuloplasty in the contemporary era. Heart Lung Circ. 2024;33:33–7. https://doi.org/10.1016/j.hlc.2023.10.019 .
doi: 10.1016/j.hlc.2023.10.019
pubmed: 38142218
O’Halloran CP, Ramlogan S, Husain N, Fox J, Nugent AW, Tannous P. Echocardiogram-guided balloon valvuloplasty of the aortic valve in neonates and infants reduces contrast exposure with maintained efficacy and less aortic regurgitation. Pediatr Cardiol. 2023. https://doi.org/10.1007/s00246-023-03188-9 .
doi: 10.1007/s00246-023-03188-9
pubmed: 37391604
Harris AG, Iacobazzi D, Caputo M, Bartoli-Leonard F. Graft rejection in paediatric congenital heart disease. Transl Pediatr. 2023;12:1572–91. https://doi.org/10.21037/tp-23-80 .
doi: 10.21037/tp-23-80
pubmed: 37692547
pmcid: 10485650
Human P, Bezuidenhout D, Aikawa E, Zilla P. Residual bioprosthetic valve immunogenicity: forgotten, not lost. Front Cardiovasc Med. 2022;8:760635.
doi: 10.3389/fcvm.2021.760635
pubmed: 35059444
pmcid: 8764456
Kostyunin AE, Yuzhalin AE, Rezvova MA, Ovcharenko EA, Glushkova TV, Kutikhin AG. Degeneration of bioprosthetic heart valves: update 2020. J Am Heart Assoc. 2020;9:e018506. https://doi.org/10.1161/JAHA.120.018506 .
doi: 10.1161/JAHA.120.018506
pubmed: 32954917
pmcid: 7792365
Kraler S, Blaser MC, Aikawa E, Camici GG, Lüscher TF. Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. Eur Heart J. 2022;43:683–97. https://doi.org/10.1093/eurheartj/ehab757 .
doi: 10.1093/eurheartj/ehab757
pubmed: 34849696
Goody PR, Hosen MR, Christmann D, Niepmann ST, Zietzer A, Adam M, Bönner F, Zimmer S, Nickenig G, Jansen F. Aortic valve stenosis: from basic mechanisms to novel therapeutic targets. Arterioscler Thromb Vasc Biol. 2020;40:885–900. https://doi.org/10.1161/atvbaha.119.313067 .
doi: 10.1161/atvbaha.119.313067
pubmed: 32160774
Chen W, Liu X, Li W, Shen H, Zeng Z, Yin K, Priest JR, Zhou Z. Single-cell transcriptomic landscape of cardiac neural crest cell derivatives during development. EMBO Rep. 2021;22:e52389. https://doi.org/10.15252/embr.202152389 .
doi: 10.15252/embr.202152389
pubmed: 34569705
pmcid: 8567227
Hulin A, Anstine LJ, Kim AJ, Potter SJ, DeFalco T, Lincoln J, Yutzey KE. Macrophage transitions in heart valve development and myxomatous valve disease. Arterioscler Thromb Vasc Biol. 2018;38:636–44. https://doi.org/10.1161/atvbaha.117.310667 .
doi: 10.1161/atvbaha.117.310667
pubmed: 29348122
pmcid: 5823761
Bartoli-Leonard F, Chelvanambi S, Pham T, Turner ME, Blaser MC, Caputo M, Aikawa M, Pang A, Muehlschlegel J, Aikawa E. Single-cell T cell receptor sequencing of paired tissue and blood samples reveals clonal expansion of CD8+ effector T cells in patients with calcific aortic valve disease. bioRxiv. 2023:2023.2007.2008.548203. https://doi.org/10.1101/2023.07.08.548203
Hulin A, Hortells L, Gomez-Stallons MV, O’Donnell A, Chetal K, Adam M, Lancellotti P, Oury C, Potter SS, Salomonis N, et al. Maturation of heart valve cell populations during postnatal remodeling. Development. 2019;146:dev.173047. https://doi.org/10.1242/dev.173047 .
doi: 10.1242/dev.173047
Raddatz MA, Madhur MS, Merryman WD. Adaptive immune cells in calcific aortic valve disease. Am J Physiol Heart Circ Physiol. 2019;317:H141-h155. https://doi.org/10.1152/ajpheart.00100.2019 .
doi: 10.1152/ajpheart.00100.2019
pubmed: 31050556
pmcid: 6692729
Hajdu Z, Romeo SJ, Fleming PA, Markwald RR, Visconti RP, Drake CJ. Recruitment of bone marrow-derived valve interstitial cells is a normal homeostatic process. J Mol Cell Cardiol. 2011;51:955–65. https://doi.org/10.1016/j.yjmcc.2011.08.006 .
doi: 10.1016/j.yjmcc.2011.08.006
pubmed: 21871458
pmcid: 3208774
Lee SH, Choi JH. Involvement of immune cell network in aortic valve stenosis: communication between valvular interstitial cells and immune cells. Immune Netw. 2016;16:26–32. https://doi.org/10.4110/in.2016.16.1.26 .
doi: 10.4110/in.2016.16.1.26
pubmed: 26937229
pmcid: 4770097
Zernecke A. Dendritic cells in atherosclerosis: evidence in mice and humans. Arterioscler Thromb Vasc Biol. 2015;35:763–70. https://doi.org/10.1161/atvbaha.114.303566 .
doi: 10.1161/atvbaha.114.303566
pubmed: 25675999
Ait-Oufella H, Sage AP, Mallat Z, Tedgui A. Adaptive (T and B Cells) Immunity and control by dendritic cells in atherosclerosis. Circ Res. 2014;114:1640–60. https://doi.org/10.1161/CIRCRESAHA.114.302761 .
doi: 10.1161/CIRCRESAHA.114.302761
pubmed: 24812352
Li G, Qiao W, Zhang W, Li F, Shi J, Dong N. The shift of macrophages toward M1 phenotype promotes aortic valvular calcification. J Thorac Cardiovasc Surg. 2017;153:1318-1327.e1311. https://doi.org/10.1016/j.jtcvs.2017.01.052 .
doi: 10.1016/j.jtcvs.2017.01.052
pubmed: 28283241
Choi J-H, Do Y, Cheong C, Koh H, Boscardin SB, Oh Y-S, Bozzacco L, Trumpfheller C, Park CG, Steinman RM. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. J Exp Med. 2009;206:497–505. https://doi.org/10.1084/jem.20082129 .
doi: 10.1084/jem.20082129
pubmed: 19221394
pmcid: 2699134
Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol. 2013;14:986–95. https://doi.org/10.1038/ni.2705 .
doi: 10.1038/ni.2705
pubmed: 24048120
pmcid: 4045180
Wang Y, Wu B, Farrar E, Lui W, Lu P, Zhang D, Alfieri CM, Mao K, Chu M, Yang D, et al. Notch-Tnf signalling is required for development and homeostasis of arterial valves. Eur Heart J. 2015;38:675–86. https://doi.org/10.1093/eurheartj/ehv520 .
doi: 10.1093/eurheartj/ehv520
pmcid: 5837252
Gottlieb Sen D, Halu A, Razzaque A, Gorham JM, Hartnett J, Seidman JG, Aikawa E, Seidman CE. The transcriptional signature of growth in human fetal aortic valve development. Ann Thorac Surg. 2018;106:1834–40. https://doi.org/10.1016/j.athoracsur.2018.06.034 .
doi: 10.1016/j.athoracsur.2018.06.034
pubmed: 30071238
Aikawa E, Whittaker P, Farber M, Mendelson K, Padera RF, Aikawa M, Schoen FJ. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation. 2006;113:1344–52. https://doi.org/10.1161/circulationaha.105.591768 .
doi: 10.1161/circulationaha.105.591768
pubmed: 16534030
Ma X, Zhao D, Yuan P, Li J, Yun Y, Cui Y, Zhang T, Ma J, Sun L, Ma H, et al. Endothelial-to-mesenchymal transition in calcific aortic valve disease. Acta Cardiol Sin. 2020;36:183–94. https://doi.org/10.6515/acs.202005_36(3).20200213a .
doi: 10.6515/acs.202005_36(3).20200213a
pubmed: 32425433
pmcid: 7220963
Driscoll K, Cruz AD, Butcher JT. Inflammatory and biomechanical drivers of endothelial-interstitial interactions in calcific aortic valve disease. Circ Res. 2021;128:1344–70. https://doi.org/10.1161/circresaha.121.318011 .
doi: 10.1161/circresaha.121.318011
pubmed: 33914601
pmcid: 8519486
Wang R, Chen W, Ma Z, Li L, Chen X. M1/M2 macrophages and associated mechanisms in congenital bicuspid aortic valve stenosis. Exp Ther Med. 2014;7:935–40. https://doi.org/10.3892/etm.2014.1529 .
doi: 10.3892/etm.2014.1529
pubmed: 24669254
pmcid: 3965126
Lupieri A, Nagata Y, Passos LSA, Beker-Greene D, Kirkwood KA, Wylie-Sears J, Alvandi Z, Higashi H, Hung JW, Singh SA, et al. Integration of functional imaging, cytometry, and unbiased proteomics reveals new features of endothelial-to-mesenchymal transition in ischemic mitral valve regurgitation in human patients. Front Cardiovasc Med. 2021;8:688396. https://doi.org/10.3389/fcvm.2021.688396 .
doi: 10.3389/fcvm.2021.688396
pubmed: 34458332
pmcid: 8387660
Shu L, Yuan Z, Li F, Cai Z. Oxidative stress and valvular endothelial cells in aortic valve calcification. Biomed Pharmacother. 2023;163:114775. https://doi.org/10.1016/j.biopha.2023.114775 .
doi: 10.1016/j.biopha.2023.114775
pubmed: 37116353
Li S, Bai Z, Quan J, Chen C. Identification of oxidative stress-related genes associated with immune cells in aortic valve stenosis based on bioinformatics analysis. Cell Mol Biol (Noisy-le-grand). 2023;69:204–9. https://doi.org/10.14715/cmb/2023.69.15.35 .
doi: 10.14715/cmb/2023.69.15.35
pubmed: 38279441
Thomas G, Tacke R, Hedrick CC, Hanna RN. Nonclassical patrolling monocyte function in the vasculature. Arterioscler Thromb Vasc Biol. 2015;35:1306–16. https://doi.org/10.1161/ATVBAHA.114.304650 .
doi: 10.1161/ATVBAHA.114.304650
pubmed: 25838429
pmcid: 4441550
Hewing B, Au SC-D, Ludwig A, Ellerbroek R, van Dijck P, Hartmann L, Grubitzsch H, Giannini C, Laule M, Stangl V, et al. Severe aortic valve stenosis in adults is associated with increased levels of circulating intermediate monocytes. J Cardiovasc Transl Res. 2017;10:27–34. https://doi.org/10.1007/s12265-016-9726-9 .
doi: 10.1007/s12265-016-9726-9
pubmed: 28097522
Schwartzenberg S, Meledin V, Zilberman L, Goland S, George J, Shimoni S. Low circulating monocyte count is associated with severe aortic valve stenosis. Isr Med Assoc J. 2013;15:500–4.
pubmed: 24340842
Abplanalp WT, Mas-Peiro S, Cremer S, John D, Dimmeler S, Zeiher AM. Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol. 2020;5:1–6. https://doi.org/10.1001/jamacardio.2020.2468 .
doi: 10.1001/jamacardio.2020.2468
pmcid: 7344831
Mazur P, Mielimonka A, Natorska J, Wypasek E, Gawęda B, Sobczyk D, Kapusta P, Malinowski KP, Kapelak B. Lymphocyte and monocyte subpopulations in severe aortic stenosis at the time of surgical intervention. Cardiovasc Pathol. 2018;35:1–7. https://doi.org/10.1016/j.carpath.2018.03.004 .
doi: 10.1016/j.carpath.2018.03.004
pubmed: 29727769
Sraeyes S, Pham DH, Gee TW, Hua J, Butcher JT. Monocytes and macrophages in heart valves: uninvited guests or critical performers? Curr Opin Biomed Eng. 2018;5:82–9. https://doi.org/10.1016/j.cobme.2018.02.003 .
doi: 10.1016/j.cobme.2018.02.003
pubmed: 30276357
pmcid: 6162070
Barrett TJ. Macrophages in atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2020;40:20–33. https://doi.org/10.1161/ATVBAHA.119.312802 .
doi: 10.1161/ATVBAHA.119.312802
pubmed: 31722535
Fadini GP, Simoni F, Cappellari R, Vitturi N, Galasso S, Vigili de Kreutzenberg S, Previato L, Avogaro A. Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis. Atherosclerosis. 2014;237:805–8. https://doi.org/10.1016/j.atherosclerosis.2014.10.106 .
doi: 10.1016/j.atherosclerosis.2014.10.106
pubmed: 25463124
Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir EAD, Amadori L, Khan NS, Wong CK, Shamailova R, Hill CA, et al. Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25:1576–88. https://doi.org/10.1038/s41591-019-0590-4 .
doi: 10.1038/s41591-019-0590-4
pubmed: 31591603
pmcid: 7318784
Johnson JL, Newby AC. Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol. 2009;20:370–8. https://doi.org/10.1097/MOL.0b013e3283309848 .
doi: 10.1097/MOL.0b013e3283309848
pubmed: 19741337
pmcid: 2850554
Grim JC, Aguado BA, Vogt BJ, Batan D, Andrichik CL, Schroeder ME, Gonzalez-Rodriguez A, Yavitt FM, Weiss RM, Anseth KS. Secreted factors from proinflammatory macrophages promote an osteoblast-like phenotype in valvular interstitial cells. Arterioscler Thromb Vasc Biol. 2020;40:e296–308. https://doi.org/10.1161/atvbaha.120.315261 .
doi: 10.1161/atvbaha.120.315261
pubmed: 32938214
pmcid: 7578003
Högerle BA, Schneider M, Sudrow K, Souidi N, Stolk M, Werner I, Biermann A, Brockbank KGM, Stock UA, Seifert M. Effects on human heart valve immunogenicity in vitro by high concentration cryoprotectant treatment. J Tissue Eng Regen Med. 2018;12:e1046–55. https://doi.org/10.1002/term.2426 .
doi: 10.1002/term.2426
pubmed: 28130912
Hjortnaes J, Butcher J, Figueiredo J-L, Riccio M, Kohler RH, Kozloff KM, Weissleder R, Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31:1975–84. https://doi.org/10.1093/eurheartj/ehq237 .
doi: 10.1093/eurheartj/ehq237
pubmed: 20601388
pmcid: 2921509
Karadimou G, Plunde O, Pawelzik SC, Carracedo M, Eriksson P, Franco-Cereceda A, Paulsson-Berne G, Bäck M. TLR7 expression is associated with M2 macrophage subset in calcific aortic valve stenosis. Cells. 2020;9:1710. https://doi.org/10.3390/cells9071710 .
doi: 10.3390/cells9071710
pubmed: 32708790
pmcid: 7407122
Liu W, Yin Y, Zhou Z, He M, Dai Y. OxLDL-induced IL-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation. Inflamm Res. 2014;63:33–43. https://doi.org/10.1007/s00011-013-0667-3 .
doi: 10.1007/s00011-013-0667-3
pubmed: 24121974
Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229–40. https://doi.org/10.1016/s0092-8674(00)81574-3 .
doi: 10.1016/s0092-8674(00)81574-3
pubmed: 9568715
Nakagawa T, Nozaki S, Nishida M, Yakub JM, Tomiyama Y, Nakata A, Matsumoto K, Funahashi T, Kameda-Takemura K, Kurata Y, et al. Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1350–7. https://doi.org/10.1161/01.atv.18.8.1350 .
doi: 10.1161/01.atv.18.8.1350
pubmed: 9714144
Nickel T, Schmauss D, Hanssen H, Sicic Z, Krebs B, Jankl S, Summo C, Fraunberger P, Walli AK, Pfeiler S, et al. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis. 2009;205:442–50. https://doi.org/10.1016/j.atherosclerosis.2009.01.002 .
doi: 10.1016/j.atherosclerosis.2009.01.002
pubmed: 19203752
Bekkering S, Quintin J, Joosten LA, van der Meer JW, Netea MG, Riksen NP. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol. 2014;34:1731–8. https://doi.org/10.1161/atvbaha.114.303887 .
doi: 10.1161/atvbaha.114.303887
pubmed: 24903093
Broeders W, Bekkering S, El Messaoudi S, Joosten LAB, van Royen N, Riksen NP. Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease? Basic Res Cardiol. 2022;117:28. https://doi.org/10.1007/s00395-022-00935-6 .
doi: 10.1007/s00395-022-00935-6
pubmed: 35581364
pmcid: 9114076
Yamada T, Satoh S, Sueyoshi S, Mitsumata M, Matsumoto T, Ueno T, Uehara K, Mizutani T. Ubiquitin-positive foam cells are identified in the aortic and mitral valves with atherosclerotic involvement. J Atheroscler Thromb. 2009;16:472–9. https://doi.org/10.5551/jat.No1248 .
doi: 10.5551/jat.No1248
pubmed: 19729866
Falkencrone S, Poulsen LK, Bindslev-Jensen C, Woetmann A, Odum N, Poulsen BC, Blom L, Jensen BM, Gibbs BF, Yasinska IM, et al. IgE-mediated basophil tumour necrosis factor alpha induces matrix metalloproteinase-9 from monocytes. Allergy. 2013;68:614–20. https://doi.org/10.1111/all.12143 .
doi: 10.1111/all.12143
pubmed: 23573943
Potaczek DP, Przytulska-Szczerbik A, Bazan-Socha S, Jurczyszyn A, Okumura K, Nishiyama C, Undas A, Wypasek E. Elements of immunoglobulin E network associate with aortic valve area in patients with acquired aortic stenosis. Biomedicines. 2020;9:23. https://doi.org/10.3390/biomedicines9010023 .
doi: 10.3390/biomedicines9010023
pubmed: 33396395
pmcid: 7824289
Akahori H, Tsujino T, Masuyama T, Ishihara M. Mechanisms of aortic stenosis. J Cardiol. 2018;71:215–20. https://doi.org/10.1016/j.jjcc.2017.11.007 .
doi: 10.1016/j.jjcc.2017.11.007
pubmed: 29258711
Hourai R, Kasashima S, Fujita SI, Sohmiya K, Daimon M, Hirose Y, Katsumata T, Kanki S, Ozeki M, Ishizaka N. A case of aortic stenosis with serum IgG4 elevation, and IgG4-positive plasmacytic infiltration in the aortic valve, epicardium, and aortic adventitia. Int Heart J. 2018;59:1149–54. https://doi.org/10.1536/ihj.17-567 .
doi: 10.1536/ihj.17-567
pubmed: 30101853
Leopold JA. Cellular mechanisms of aortic valve calcification. Circ Cardiovasc Interv. 2012;5:605–14. https://doi.org/10.1161/circinterventions.112.971028 .
doi: 10.1161/circinterventions.112.971028
pubmed: 22896576
pmcid: 3427002
Miller JD, Weiss RM, Heistad DD, Towler DA. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res. 2011;108:1392–412. https://doi.org/10.1161/CIRCRESAHA.110.234138 .
doi: 10.1161/CIRCRESAHA.110.234138
pubmed: 21617136
pmcid: 3150727
Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, Weyand CM. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101:2883–8. https://doi.org/10.1161/01.cir.101.25.2883 .
doi: 10.1161/01.cir.101.25.2883
pubmed: 10869258
Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1995;92:3893–7. https://doi.org/10.1073/pnas.92.9.3893 .
doi: 10.1073/pnas.92.9.3893
pubmed: 7732003
pmcid: 42068
Andreae J, Galle C, Magdorf K, Staab D, Meyer L, Goldman M, Querfeld U. Severe atherosclerosis of the aorta and development of peripheral T-cell lymphoma in an adolescent with angiolymphoid hyperplasia with eosinophilia. Br J Dermatol. 2005;152:1033–8. https://doi.org/10.1111/j.1365-2133.2005.06421.x .
doi: 10.1111/j.1365-2133.2005.06421.x
pubmed: 15888166
Bondarenko S, Catapano AL, Norata GD. The CD1d-natural killer T cell axis in atherosclerosis. J Innate Immun. 2014;6:3–12. https://doi.org/10.1159/000351034 .
doi: 10.1159/000351034
pubmed: 23774666
Depuydt MAC, Schaftenaar FH, Prange KHM, Boltjes A, Hemme E, Delfos L, de Mol J, de Jong MJM, Bernabé Kleijn MNA, Peeters JAHM, et al. Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells. Nat Cardiovasc Res. 2023;2:112–25. https://doi.org/10.1038/s44161-022-00208-4 .
doi: 10.1038/s44161-022-00208-4
pubmed: 38665903
pmcid: 11041750
Blaser MC, Kraler S, Lüscher TF, Aikawa E. Network-guided multiomic mapping of aortic valve calcification. Arterioscler Thromb Vasc Biol. 2023;43:417–26. https://doi.org/10.1161/atvbaha.122.318334 .
doi: 10.1161/atvbaha.122.318334
pubmed: 36727519
pmcid: 9975082
Staal AHJ, Cortenbach KRG, Gorris MAJ, van der Woude LL, Srinivas M, Heijmen RH, Geuzebroek GSC, Grewal N, Hebeda KM, de Vries IJM, et al. Adventitial adaptive immune cells are associated with ascending aortic dilatation in patients with a bicuspid aortic valve. Front Cardiovasc Med. 2023;10:1127685. https://doi.org/10.3389/fcvm.2023.1127685 .
doi: 10.3389/fcvm.2023.1127685
pubmed: 37057097
pmcid: 10086356
Xu K, Xie S, Huang Y, Zhou T, Liu M, Zhu P, Wang C, Shi J, Li F, Sellke FW, et al. Cell-type transcriptome atlas of human aortic valves reveal cell heterogeneity and endothelial to mesenchymal transition involved in calcific aortic valve disease. Arterioscler Thromb Vasc Biol. 2020;40:2910–21. https://doi.org/10.1161/atvbaha.120.314789 .
doi: 10.1161/atvbaha.120.314789
pubmed: 33086873
van Duijn J, Kritikou E, Benne N, van der Heijden T, van Puijvelde GH, Kröner MJ, Schaftenaar FH, Foks AC, Wezel A, Smeets H, et al. CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses. Cardiovasc Res. 2019;115:729–38. https://doi.org/10.1093/cvr/cvy261 .
doi: 10.1093/cvr/cvy261
pubmed: 30335148
Mazzone A, Epistolato MC, De Caterina R, Storti S, Vittorini S, Sbrana S, Gianetti J, Bevilacqua S, Glauber M, Biagini A, et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol. 2004;43:1670–6. https://doi.org/10.1016/j.jacc.2003.12.041 .
doi: 10.1016/j.jacc.2003.12.041
pubmed: 15120829
Shimoni S, Bar I, Meledin V, Gandelman G, George J. Circulating regulatory T cells in patients with aortic valve stenosis: association with disease progression and aortic valve intervention. Int J Cardiol. 2016;218:181–7. https://doi.org/10.1016/j.ijcard.2016.05.039 .
doi: 10.1016/j.ijcard.2016.05.039
pubmed: 27236112
Jian B, Narula N, Li QY, Mohler ER 3rd, Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003;75:457–65. https://doi.org/10.1016/s0003-4975(02)04312-6 . (discussion 465-456).
doi: 10.1016/s0003-4975(02)04312-6
pubmed: 12607654
El Husseini D, Boulanger MC, Mahmut A, Bouchareb R, Laflamme MH, Fournier D, Pibarot P, Bossé Y, Mathieu P. P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease. J Mol Cell Cardiol. 2014;72:146–56. https://doi.org/10.1016/j.yjmcc.2014.02.014 .
doi: 10.1016/j.yjmcc.2014.02.014
pubmed: 24631773
Liu Z, Wang Y, Shi J, Chen S, Xu L, Li F, Dong N. IL-21 promotes osteoblastic differentiation of human valvular interstitial cells through the JAK3/STAT3 pathway. Int J Med Sci. 2020;17:3065–72. https://doi.org/10.7150/ijms.49533 .
doi: 10.7150/ijms.49533
pubmed: 33173427
pmcid: 7646116
Cano-Gamez E, Soskic B, Roumeliotis TI, So E, Smyth DJ, Baldrighi M, Willé D, Nakic N, Esparza-Gordillo J, Larminie CGC, et al. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4(+) T cells to cytokines. Nat Commun. 2020;11:1801. https://doi.org/10.1038/s41467-020-15543-y .
doi: 10.1038/s41467-020-15543-y
pubmed: 32286271
pmcid: 7156481
Ou HX, Guo BB, Liu Q, Li YK, Yang Z, Feng WJ, Mo ZC. Regulatory T cells as a new therapeutic target for atherosclerosis. Acta Pharmacol Sin. 2018;39:1249–58. https://doi.org/10.1038/aps.2017.140 .
doi: 10.1038/aps.2017.140
pubmed: 29323337
pmcid: 6289392
Kudryavtsev I, Serebriakova M, Zhiduleva E, Murtazalieva P, Titov V, Malashicheva A, Shishkova A, Semenova D, Irtyuga O, Isakov D, et al. CD73 rather than CD39 is mainly involved in controlling purinergic signaling in calcified aortic valve disease. Front Genet. 2019;10:604. https://doi.org/10.3389/fgene.2019.00604 .
doi: 10.3389/fgene.2019.00604
pubmed: 31402927
pmcid: 6669234
Nagy E, Lei Y, Martínez-Martínez E, Body SC, Schlotter F, Creager M, Assmann A, Khabbaz K, Libby P, Hansson GK, et al. Interferon-γ released by activated CD8(+) T lymphocytes impairs the calcium resorption potential of osteoclasts in calcified human aortic valves. Am J Pathol. 2017;187:1413–25. https://doi.org/10.1016/j.ajpath.2017.02.012 .
doi: 10.1016/j.ajpath.2017.02.012
pubmed: 28431214
pmcid: 5455058
Shuvy M, Ben Ya’acov A, Zolotarov L, Lotan C, Ilan Y. Beta glycosphingolipids suppress rank expression and inhibit natural killer T cell and CD8+ accumulation in alleviating aortic valve calcification. Int J Immunopathol Pharmacol. 2009;22:911–8. https://doi.org/10.1177/039463200902200406 .
doi: 10.1177/039463200902200406
pubmed: 20074454
Lindman BR, Fonarow GC, Myers G, Alger HM, Rutan C, Troll K, Aringo A, Shahriary M, Jessup M, Arnold SV, et al. Target aortic stenosis: a national initiative to improve quality of care and outcomes for patients with aortic stenosis. Circ Cardiovasc Qual Outcomes. 2023;16:e009712. https://doi.org/10.1161/circoutcomes.122.009712 .
doi: 10.1161/circoutcomes.122.009712
pubmed: 37339188
Tucker B, Sawant S, McDonald H, Rye KA, Patel S, Ong KL, Cochran BJ. The association of serum lipid and lipoprotein levels with total and differential leukocyte counts: results of a cross-sectional and longitudinal analysis of the UK Biobank. Atherosclerosis. 2021;319:1–9. https://doi.org/10.1016/j.atherosclerosis.2020.12.016 .
doi: 10.1016/j.atherosclerosis.2020.12.016
pubmed: 33453490
Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Grégoire J, Grover SA, et al. 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37:1129–50. https://doi.org/10.1016/j.cjca.2021.03.016 .
doi: 10.1016/j.cjca.2021.03.016
pubmed: 33781847
Kostyunin A, Mukhamadiyarov R, Glushkova T, Bogdanov L, Shishkova D, Osyaev N, Ovcharenko E, Kutikhin A. Ultrastructural pathology of atherosclerosis, calcific aortic valve disease, and bioprosthetic heart valve degeneration: commonalities and differences. Int J Mol Sci. 2020;21:7434. https://doi.org/10.3390/ijms21207434 .
doi: 10.3390/ijms21207434
pubmed: 33050133
pmcid: 7587971
Zhong S, Li L, Shen X, Li Q, Xu W, Wang X, Tao Y, Yin H. An update on lipid oxidation and inflammation in cardiovascular diseases. Free Radic Biol Med. 2019;144:266–78. https://doi.org/10.1016/j.freeradbiomed.2019.03.036 .
doi: 10.1016/j.freeradbiomed.2019.03.036
pubmed: 30946962
Kutryb-Zajac B, Jablonska P, Serocki M, Bulinska A, Mierzejewska P, Friebe D, Alter C, Jasztal A, Lango R, Rogowski J, et al. Nucleotide ecto-enzyme metabolic pattern and spatial distribution in calcific aortic valve disease; its relation to pathological changes and clinical presentation. Clin Res Cardiol. 2020;109:137–60. https://doi.org/10.1007/s00392-019-01495-x .
doi: 10.1007/s00392-019-01495-x
pubmed: 31144065
Schlotter F, de Freitas RCC, Rogers MA, Blaser MC, Wu PJ, Higashi H, Halu A, Iqbal F, Andraski AB, Rodia CN, Kuraoka S, Wen JR, Creager M, Pham T, Hutcheson JD, Body SC, Kohan AB, Sacks FM, Aikawa M, Singh SA, Aikawa E. ApoC-III is a novel inducer of calcification in human aortic valves. J Biol Chem. 2021;296:100193. https://doi.org/10.1074/jbc.RA120.015700 .
Capoulade R, Torzewski M, Mayr M, Chan KL, Mathieu P, Bossé Y, Dumesnil JG, Tam J, Teo KK, Burnap SA, et al. ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. Heart. 2020;106:738–45. https://doi.org/10.1136/heartjnl-2019-315840 .
doi: 10.1136/heartjnl-2019-315840
pubmed: 32054669
Guddeti RR, Patil S, Ahmed A, Sharma A, Aboeata A, Lavie CJ, Alla VM. Lipoprotein(a) and calcific aortic valve stenosis: a systematic review. Prog Cardiovasc Dis. 2020;63:496–502. https://doi.org/10.1016/j.pcad.2020.06.002 .
doi: 10.1016/j.pcad.2020.06.002
pubmed: 32526213
Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WSA, Doris MK, White AC, Timmers N, Hjortnaes J, Rogers MA, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73:2150–62. https://doi.org/10.1016/j.jacc.2019.01.070 .
doi: 10.1016/j.jacc.2019.01.070
pubmed: 31047003
pmcid: 6494952
Small A, Kiss D, Giri J, Anwaruddin S, Siddiqi H, Guerraty M, Chirinos JA, Ferrari G, Rader DJ. Biomarkers of calcific aortic valve disease. Arterioscler Thromb Vasc Biol. 2017;37:623–32. https://doi.org/10.1161/ATVBAHA.116.308615 .
doi: 10.1161/ATVBAHA.116.308615
pubmed: 28153876
pmcid: 5364059
Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–97. https://doi.org/10.1056/NEJMoa043876 .
doi: 10.1056/NEJMoa043876
pubmed: 15944423
Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306–14. https://doi.org/10.1161/circulationaha.109.900027 .
doi: 10.1161/circulationaha.109.900027
pubmed: 20048204
Lehrer-Graiwer J, Singh P, Abdelbaky A, Vucic E, Korsgren M, Baruch A, Fredrickson J, van Bruggen N, Tang MT, Frendeus B, et al. FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc Imaging. 2015;8:493–4. https://doi.org/10.1016/j.jcmg.2014.06.021 .
doi: 10.1016/j.jcmg.2014.06.021
pubmed: 25457756
Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging. 2012;5:911–22. https://doi.org/10.1016/j.jcmg.2012.02.016 .
doi: 10.1016/j.jcmg.2012.02.016
pubmed: 22974804
Suzuki K, Takahashi S, Watanabe K, Fujioka D, Nakamura T, Obata JE, Kawabata K, Katoh R, Matsumoto M, Kugiyama K. The expression of groups IIE and V phospholipase A2 is associated with an increased expression of osteogenic molecules in human calcified aortic valves. J Atheroscler Thromb. 2014;21:1308–25. https://doi.org/10.5551/jat.24273 .
doi: 10.5551/jat.24273
pubmed: 25132377
Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol. 2010;56:1079–88. https://doi.org/10.1016/j.jacc.2010.06.015 .
doi: 10.1016/j.jacc.2010.06.015
pubmed: 20863951
Gaztanaga J, Farkouh M, Rudd JH, Brotz TM, Rosenbaum D, Mani V, Kerwin TC, Taub R, Tardif JC, Tawakol A, et al. A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. Atherosclerosis. 2015;240:53–60. https://doi.org/10.1016/j.atherosclerosis.2015.02.027 .
doi: 10.1016/j.atherosclerosis.2015.02.027
pubmed: 25752438
Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, Manolescu A, Arnar DO, Andersen K, Sigurdsson A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA. 2005;293:2245–56. https://doi.org/10.1001/jama.293.18.2245 .
doi: 10.1001/jama.293.18.2245
pubmed: 15886380
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914 .
doi: 10.1056/NEJMoa1707914
pubmed: 28845751
Bartoli-Leonard F, Aikawa E. Old drugs for an old pathology? Drug repurposing for calcific aortic valve disease. Circ Res. 2021;128:1317–9. https://doi.org/10.1161/CIRCRESAHA.121.319149 .
doi: 10.1161/CIRCRESAHA.121.319149
pubmed: 33914606
pmcid: 8095786
Dutta P, Kodigepalli KM, LaHaye S, Thompson JW, Rains S, Nagel C, Thatcher K, Hinton RB, Lincoln J. KPT-330 prevents aortic valve calcification via a novel C/EBPβ signaling pathway. Circ Res. 2021;128:1300–16. https://doi.org/10.1161/CIRCRESAHA.120.318503 .
doi: 10.1161/CIRCRESAHA.120.318503
pubmed: 33601919
pmcid: 8085092
Hutcheson JD, Aikawa E, Merryman WD. Potential drug targets for calcific aortic valve disease. Nat Rev Cardiol. 2014;11:218–31. https://doi.org/10.1038/nrcardio.2014.1 .
doi: 10.1038/nrcardio.2014.1
pubmed: 24445487
pmcid: 4263317
Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42:113–31. https://doi.org/10.1093/eurheartj/ehaa099 .
doi: 10.1093/eurheartj/ehaa099
pubmed: 32176778
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21. https://doi.org/10.1056/NEJMoa1701719 .
doi: 10.1056/NEJMoa1701719
pubmed: 28636844
pmcid: 6717509
Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91–6. https://doi.org/10.1126/science.abm0594 .
doi: 10.1126/science.abm0594
pubmed: 34990237
pmcid: 9983611
Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021;12:613. https://doi.org/10.1038/s41467-021-20903-3 .
doi: 10.1038/s41467-021-20903-3
pubmed: 33504774
pmcid: 7840919
Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metab. 2022;4:163–9. https://doi.org/10.1038/s42255-022-00537-5 .
doi: 10.1038/s42255-022-00537-5
pubmed: 35228742
pmcid: 9947862
Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature. 1999;402:6–13. https://doi.org/10.1038/35005508 .
doi: 10.1038/35005508
Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med. 2009;206:849–66. https://doi.org/10.1084/jem.20081382 .
doi: 10.1084/jem.20081382
pubmed: 19332877
pmcid: 2715122
Pettmann J, Huhn A, Shah EA, Kutuzov MA, Wilson DB, Dustin ML, Davis, van der Merwe PA, Dushek O. The discriminatory power of the T cell receptor. eLife. 2021;10:e67092. https://doi.org/10.7554/eLife.67092
June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73. https://doi.org/10.1056/NEJMra1706169 .
doi: 10.1056/NEJMra1706169
pubmed: 29972754
pmcid: 7433347
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94:S3–9. https://doi.org/10.1002/ajh.25418 .
doi: 10.1002/ajh.25418
pubmed: 30680780
Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36:494–502. https://doi.org/10.1016/j.it.2015.06.004 .
doi: 10.1016/j.it.2015.06.004
pubmed: 26169254
pmcid: 4746114
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. https://doi.org/10.1038/s41408-021-00459-7 .
doi: 10.1038/s41408-021-00459-7
pubmed: 33824268
pmcid: 8024391
Rurik JG, Aghajanian H, Epstein JA. Immune cells and immunotherapy for cardiac injury and repair. Circ Res. 2021;128:1766–79. https://doi.org/10.1161/circresaha.121.318005 .
doi: 10.1161/circresaha.121.318005
pubmed: 34043424
pmcid: 8171813
Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583:127–32. https://doi.org/10.1038/s41586-020-2403-9 .
doi: 10.1038/s41586-020-2403-9
pubmed: 32555459
pmcid: 7583560
Guedan S, Calderon H, Posey AD Jr, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145–56. https://doi.org/10.1016/j.omtm.2018.12.009 .
doi: 10.1016/j.omtm.2018.12.009
pubmed: 30666307